Netherlands· NL-ee64fa181a0f
Upstaza 2,8 x 10^11 vg/0.5 ml, oplossing voor infusie
A other nervous system drugs product containing eladocageen exuparvovec, registered in Netherlands by PTC Therapeutics International Limited. The same ATC class is registered in 3 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Eladocageen exuparvovec is registered in 3 of 19 countries.
Countries holding a registration under ATC N07 (other nervous system drugs), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 1 of them publish a price we can compare per daily dose
Eladocageen exuparvovec · ATC N07
3 / 19 countries
- Finlandprice
- Ireland
- Netherlands
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ELADOCAGEEN EXUPARVOVEC
- Manufacturer
- PTC Therapeutics International Limited
- Country
- Netherlands (NL)
- ATC code
- N07
- ATC class
- OTHER NERVOUS SYSTEM DRUGS
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/22/1653
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eladocageen exuparvovec in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKEBILIDIPTC Therapeutics, Inc.
- CzechiaUPSTAZAPTC Therapeutics International Limited, Dublin 2
- SpainUPSTAZA 2,8 × 10E11 GENOMAS VECTORIALES (VG)/0,5 ML PARA SOLUCION PARA PERFUSIONPtc Therapeutics International Limited
- FinlandUpstazaPTC Therapeutics International limited
- FranceUPSTAZA 2,8 x 100 000 000 000 génomes de vecteur (vg)/0,5 mL, solution pour perfusionPTC THERAPEUTICS INTERNATIONAL (IRLANDE)
- BelgiumUpstaza 2.8 10*11 vg/0.5 mlPTC Therapeutics International
- IrelandUpstaza 2.8 × 10^11 vector genomes/0.5 mL solution for infusionPTC Therapeutics International Limited
- IcelandUpstazaPTC Therapeutics International Limited*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Upstaza
- Liechtenstein · Upstaza
- Norway · Upstaza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0ae87c6f-4fdc-4997-be39-a58c1c1e1c1b GET /v1/drugs/0ae87c6f-4fdc-4997-be39-a58c1c1e1c1b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor infusie",
"route": "Intracerebraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/upstaza-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Other Nervous System Drugs",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126214",
"excipients": [
"DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
"KALIUMCHLORIDE (E 508)",
"KALIUMDIWATERSTOFFOSFAAT 0-WATER (E 340)",
"NATRIUMCHLORIDE",
"POLOXAMEER 188",
"WATER VOOR INJECTIE"
],
"substances": [
"ELADOCAGEEN EXUPARVOVEC"
],
"leaflet_url": null,
"authorised_at": "2022/07/18",
"procedure_number": "EMEA/H/C/005352",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/22/1653",
"additional_monitoring": "N"
}See everything about eladocageen exuparvovec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.